As per the latest RNS: "MED's Pyebridge site has secured further Capacity Market contracts to ensure minimum annual gross profit margin income totaling c. £817,000 until 2028". Seems pretty clear to me the 817 figure is per annum.
Aether you keep your mouth shut. I remember damn well how you showed up here out of the blue on the morning of Feb 21st looking to make a quick buck no doubt. Most of us here see through the hot air that you spout. “Green bin it don’t feed it” will be the response.
Aethers first post here was on Feb 21st if I remember correctly. Let guess what the response will be.'Green bin it. Dont feed it. Lights out soon for Synairgen'. Obvious troll repeating the same stupid mantras over and over if you ask me. That or perhaps he's a buddhist monk!
The sp has declined in the absence of positive RNS-worthy news, as is the case with more or less all AIM shares. Short term catalysts anticipated here include news regarding positive ACTIV P2 data as well as the launch of a redesigned US trial and the possibility of inclusion on said trial. DYOR
RE: STRIVE will make Synairgen go to £7 per share17 Aug 2022 17:53
£10. There is significant upside here ASSUMING inclusion of SNG001 on a new trial. Without that it goes without saying the share price will decline, but I do not think that will be the case. Any investor who thinks the only way is down would surely sell up and move their money elsewhere??